[Home ] [Archive]    
:: Main :: About :: Current Issue :: Archive :: Search :: Submit :: Contact ::
:: Volume 20, Issue 2 (4-2022) ::
Int J Radiat Res 2022, 20(2): 347-352 Back to browse issues page
HS-173, a novel PI3K inhibitor enhances radiosensitivity of breast cancer cells
H. Lee, J.H. Park, K.H. Jung, J.H. Lim, S-S. Hong
Department of Medicine, College of Medicine, and Program in Biomedical Science & Engineering, Inha University, Incheon, Republic of Korea , hongs@inha.ac.kr
Abstract:   (434 Views)
Background: The development of radiosensitizers that modulate activated signaling pathways has enhanced effective cancer treatment via radiation therapy. The phosphoinositide 3-kinases (PI3K)/protein kinase B (AKT) pathway induces cancer progression and radioresistance. Therefore, we investigated if HS-173, a novel PI3K inhibitor, could increase the radiosensitivity in breast cancer cells. Materials and Methods: Breast cancer cell lines (MCF-7, BT-474, and T47D, MDA-MB-231) were exposed to radiation (28 Gy). After irradiation, cell viability was assessed using the MTT assay. MDA-MB-231 cells were exposed to radiation (5 Gy) alone and/or in combination with HS-173 (1 μM). After treatment, the levels of PI3K/AKT signaling protein were measured using western blotting. The radiosensitivity of HS-173 was assessed using a clonogenic assay and flow cytometry. Results: We observed that HS-173 decreased the radiation-induced phosphorylation of AKT in MDA-MB-231 cells and increased their radiosensitivity in the clonogenic assay. Upon investigation of the mechanism underlying the enhanced radiosensitivity by HS-173, we observed a significant increase in the IR-induced G2/M cell cycle arrest and apoptosis pathway components, including poly (ADP-ribose) polymerase (PARP-1) and cleaved caspase-3. It can be concluded that HS-173 significantly improved radiosensitivity by inducing apoptosis and G2/M arrest in radio-resistant breast cancer cells. Conclusion: HS-173 may be applied as a radiosensitizer with promising potential in radio-resistant breast cancer treatment.
 
 
Keywords: PI3K, HS-173, radiosensitizer, breast cancer
Full-Text [PDF 1768 kb]   (234 Downloads)    
Type of Study: Original Research | Subject: Radiation Biology
Send email to the article author

Add your comments about this article
Your username or Email:

CAPTCHA



XML     Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Lee H, Park J, Jung K, Lim J, Hong S. HS-173, a novel PI3K inhibitor enhances radiosensitivity of breast cancer cells. Int J Radiat Res 2022; 20 (2) :347-352
URL: http://ijrr.com/article-1-4265-en.html


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Volume 20, Issue 2 (4-2022) Back to browse issues page
International Journal of Radiation Research
Persian site map - English site map - Created in 0.04 seconds with 32 queries by YEKTAWEB 4509